Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA101 + Ibrutinib and MRD-driven Strategy in CLL
NCT02666898Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Oct 2015
- Primary completion
- May 2017
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab, ibrutinib in chronic lymphocytic leukemia (CLL), sponsored by French Innovative Leukemia Organisation. Started Oct 2015; status: completed.
02
Drugs
obinutuzumabibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02666898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666898.